StockWatch
·

Research Reports

06 Nov 2026
ALIVUSGlenmark Life Sciences Ltd

Margin Upgrade Credible, But This Quarter's Not Repeatable

margin expansion · one-off inflated · CDMO growth

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
NOVARTINDNOVARTIS INDIA LTD.

Restructuring Loss Masks a Business That's Still Burning

spin-off · customer concentration · unprofitable

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
NOVARTINDNOVARTIS INDIA LTD.

Restructuring loss masks weak underlying; long-term upside hinges on execution

spin-off transition · distribution rebuild · brand relicensing

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
KAYAKaya Ltd

Kaya turns operating-profit positive in Q2 FY27; standalone net loss narrows 33% YoY

skincare · going concern · margin turnaround

ResultsQ2 FY273 minPharma & Healthcare
SUPRIYASupriya Lifescience Ltd

Supriya Q2 FY27: standalone PAT -42% YoY, margins compress to 22%

pharma api · margin compression · revenue deceleration

ResultsQ2 FY273 minPharma & Healthcare
GRANULESGRANULES INDIA LTD.-$

Growth That Masks Its Own Weaknesses

margin compression · cash flow risk · FDA observations

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
GRANULESGRANULES INDIA LTD.-$

Strong growth masked by margin compression and cash flow decline

revenue growth · margin pressure · FDA observations

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
05 Nov 2026
AMBALALSAAMBALAL SARABHAI ENTERPRISES LTD.

ASE swings to ₹0.67 Cr consolidated profit in Q2 FY27 as revenue grows 31% YoY

pharmaceuticals · electronics · consolidated turnaround

ResultsQ2 FY273 minPharma & Healthcare
HIKALHIKAL LTD.

36% growth, ₹6 crore loss: Hikal's profitability promise stalls

raw materials inflation · FDA remediation · crop protection loss

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
HIKALHIKAL LTD.

Strong revenue growth masks loss: profitability deteriorated

revenue growth 36% · PAT loss -6 Cr · FDA remediation headwind

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
RUBICONRubicon Research Ltd

Rubicon Research Q2FY27: consolidated PAT +68% YoY to ₹90.4 Cr, OPM expands to 25%

pharmaceuticals · margin expansion · inorganic growth

ResultsQ2 FY273 minPharma & Healthcare
SIGACHISigachi Industries Ltd

Growth masked by margin squeeze

margin compression · guidance cut · MCC expansion

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
SIGACHISigachi Industries Ltd

Revenue growth masks PAT collapse; guidance cut

MCC expansion delay · PAT compression · capacity utilization

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
AKUMSAkums Drugs and Pharmaceuticals Ltd

CDMO Powers 32%, But Baddi Capex and Zambia Slip Narrow the Path

CDMO · volume growth · Baddi capex

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
AKUMSAkums Drugs and Pharmaceuticals Ltd

Strong CDMO, margins held; near-term capex & Zambia slip limit upside

CDMO volume growth · EBITDA expansion · Baddi capex ramp

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
SUVENSUVEN LIFE SCIENCES LTD.

Consolidated loss widens 38% YoY to ₹106.9 Cr as Phase 3 trial R&D spend climbs 43%

clinical stage biopharma · phase 3 trials · alzheimers trial

ResultsQ2 FY273 minPharma & Healthcare
SHILPAMEDSHILPA MEDICARE LTD.

Shilpa Medicare Q2 FY27: PAT +80% YoY to ₹79 Cr, revenue +43%, op margin slips 240bps

pharmaceuticals · cdmo · biologics

ResultsQ2 FY273 minPharma & Healthcare
FERMENTAFermenta Biotech Ltd

Fermenta Biotech Q2 FY27: consolidated PAT down 48% YoY, NPM compresses to 6.9%

bulk drugs chemicals · vitamin b12 · overseas subsidiary losses

ResultsQ2 FY273 minPharma & Healthcare
BLUEJETBlue Jet Healthcare Ltd

Blue Jet Q2 FY27: revenue +127% YoY to ₹375.7 Cr, PAT +97% to ₹102.5 Cr; margins dip

pharma intermediates · contrast media · qip capital raise

ResultsQ2 FY273 minPharma & Healthcare
FREDUNFredun Pharmaceuticals Ltd

Fredun Pharma Q2 FY27: PAT nearly doubles YoY (+97%), outpacing 86% revenue growth

pharmaceuticals manufacturing · margin expansion · profit outpaces revenue

ResultsQ2 FY273 minPharma & Healthcare
HESTERBIOHESTER BIOSCIENCES LTD.

Hester Biosciences Q2 FY27: consolidated PAT +44% YoY as EBITDA margin expands to 37%

animal health · vaccines · poultry healthcare

ResultsQ2 FY273 minPharma & Healthcare
04 Nov 2026
AARTIPHARMAarti Pharmalabs Ltd

Record growth masks rising execution risk — Xanthine guidance cut signals caution

Xanthine guidance cut · CDMO growth · working capital strain

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
AARTIPHARMAarti Pharmalabs Ltd

Record growth masks capex intensity, Xanthine guidance cut signals caution

Xanthine price normalization · CDMO 40-50% growth · Capex ₹350-400 Cr

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
VIMTALABSVIMTA LABS LTD.-$

Growth stalls at 10%, margins hold; recovery in early innings

R&D pipeline slowdown · biologics ramp · preclinical CAGR 30%

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
ZIMLABZim Laboratories Ltd

Zim Labs: consolidated loss widens YoY to ₹2.05 Cr despite 19% revenue growth, eases QoQ

pharma exports · margin compression · revenue growth

ResultsQ2 FY273 minPharma & Healthcare
APLLTDALEMBIC PHARMACEUTICALS LTD.

Alembic Pharma Q2FY27: consolidated PAT +82% YoY to ₹334 Cr, margins expand sharply

pharmaceuticals · margin expansion · us generics

ResultsQ2 FY273 minPharma & Healthcare
MARKSANSMARKSANS PHARMA LTD.

Marksans Q2 FY27: consolidated PAT +45% YoY to ₹143.5 Cr, margins ease off Q1's record

pharma generics · margin expansion · europe expansion

ResultsQ2 FY273 minPharma & Healthcare
LALPATHLABDr. Lal PathLabs Ltd

Dr Lal PathLabs Q2 FY27: consolidated PAT +27% YoY, margins expand, beats growth guidance

diagnostics · margin expansion · revenue growth

ResultsQ2 FY273 minPharma & Healthcare
SMSPHARMASMS PHARMACEUTICALS LTD.

SMS Pharma Q2 FY27: PAT +57% YoY to ₹39.9 Cr on consolidated basis, margins expand

active pharmaceutical ingredients · api manufacturing · margin expansion

ResultsQ2 FY273 minPharma & Healthcare
BIOCONBIOCON LTD.

Biocon Q2 FY27: Consolidated PAT Falls 57% YoY on Biosimilars Margin Collapse

biosimilars · margin compression · segment results

ResultsQ2 FY273 minPharma & Healthcare